Longeveron (LGVN) Accounts Payables (2022 - 2026)
Longeveron (LGVN) recorded quarterly Accounts Payables of $293000.0 in Q1 2026, down 30.73% quarter-over-quarter from $423000.0 in Q4 2025, and down 20.16% on a YoY basis from $367000.0 in Q1 2025.
Longeveron (LGVN) Accounts Payables (2022 - 2026) Analysis & Trends
Longeveron's Accounts Payables history runs 5 years deep, the most recent figure standing at $293000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 20.16% year-over-year to $293000.0; the TTM figure through Mar 2026 stood at $293000.0 (down 20.16% YoY), while the FY2025 annual figure was $423000.0, up 327.27% from the prior year.
- Accounts Payables was $293000.0 for Q1 2026 at Longeveron, down from $423000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.8 million in Q4 2022 to a low of $99000.0 in Q4 2024.
- Historically, Accounts Payables has averaged $833384.6 across 5 years, with a median of $700000.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 84.48% in 2024, then jumped 327.27% in 2025.
- A 5-year view of Accounts Payables shows it stood at $1.8 million in 2022, then slumped by 63.56% to $638000.0 in 2023, then tumbled by 84.48% to $99000.0 in 2024, then surged by 327.27% to $423000.0 in 2025, then sank by 30.73% to $293000.0 in 2026.
- The last three Accounts Payables figures came in at $293000.0 (Q1 2026), $423000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.64 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 293,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293,000.00 |
| Dec 31, 2025 | 423,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 367,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 887,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 638,000.00 |
| Sep 30, 2023 | 829,000.00 |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 1.75 Mn |